C16 Biosciences: Funding, Investors & Team (Sep 2026)
C16 Biosciences was established in 2017 with the objective of utilizing microbiology to create sustainable alternatives to palm oil. The firm's goal is to offer producers, refiners, traders, and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability initiatives, which would help reduce the environmental impact of palm oil production and safeguard natural land, wildlife, and resources. C16 Biosciences believes that fermenting palm oil, similar to brewing beer, is the most effective method of creating a truly sustainable alternative. As a result of their efforts, consumers can enjoy their favorite products without having to worry about the devastating impact of unethically produced palm oil on wildlife and communities.
C16 Biosciences has raised $26.0M across 4 funding rounds on record, the most recent an undisclosed round of $1.0M announced in Jan 2024.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
C16 Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2024.
C16 Biosciences Funding Rounds
1 of 4 rounds was announced without a disclosed amount and is excluded from the total.
C16 Biosciences raised $20.0M in an undisclosed round announced in Mar 2020.
3 years later, an undisclosed round of $5.0M was announced in Mar 2023.
7 months later, an undisclosed round was announced in Oct 2023 with no disclosed amount.
3 months later, an undisclosed round of $1.0M was announced in Jan 2024.
C16 Biosciences Founders and Leadership Team
Contact details for the C16 Biosciences team: 2 of 2 have an email address on file.
Start 14-day free trial →C16 Biosciences Funding Compared to Other Biotechnology Startups
C16 Biosciences' latest round of $1.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like C16 Biosciences in Biotechnology and New York
Companies Similar to C16 Biosciences
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
C16 Biosciences Funding FAQs
What does C16 Biosciences do?
C16 Biosciences was established in 2017 with the objective of utilizing microbiology to create sustainable alternatives to palm oil. The firm's goal is to offer producers, refiners, traders, and consumers of palm oil an opportunity to invest part of their production into bio-based oils and sustainability initiatives, which would help reduce the environmental impact of palm oil production and safeguard natural land, wildlife, and resources. C16 Biosciences believes that fermenting palm oil, similar to brewing beer, is the most effective method of creating a truly sustainable alternative. As a result of their efforts, consumers can enjoy their favorite products without having to worry about the devastating impact of unethically produced palm oil on wildlife and communities.
How much funding has C16 Biosciences raised?
C16 Biosciences has raised $26.0M across 4 rounds on record. The most recent is an undisclosed round of $1.0M announced in Jan 2024.
When did C16 Biosciences last raise funding?
C16 Biosciences' most recent funding round on record is an undisclosed round of $1.0M, announced in Jan 2024.
Who founded C16 Biosciences?
FundedIQ lists David Heller (Founder) at C16 Biosciences.
Who is the CEO of C16 Biosciences?
Shara Ticku is listed as CEO at C16 Biosciences.
Where is C16 Biosciences headquartered?
C16 Biosciences is based in New York, United States.
How many employees does C16 Biosciences have?
C16 Biosciences is in the 11-50 employee band.
How does C16 Biosciences' funding compare to other Biotechnology startups?
C16 Biosciences' latest round of $1.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's C16 Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for C16 Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.